Quote:
Originally Posted by joelfmi
Experimental Alzheimer's drug may slow cognitive decline
The experimental intravenous drug donanemab may slow cognitive decline in people living with Alzheimer's, according to a Phase 2 clinical trial. Researchers found that the drug slowed the decline of cognition and daily function in participants by 32 percent after 76 weeks compared to those who received a placebo. The research is early, but Maria Carrillo, Alzheimer’s Association chief science officer, says the drug “could be a first step toward slowing more significantly, or stopping, cognitive decline in these earlier stages."

|
Right now I like the prospect of A273 from Anavex Life Sciences even better. It's also being tested on Parkinson's Disease and Rett Syndrome. In addition, they hope to test it on several other CNS diseases. They take a completely different avenue attacking brain issues than big pharma does.